Iovance Biotherapeutics, Inc.
IOVAIovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Drugs in Pipeline
8
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
IOVA Earnings Report
EPS Est: $-0.17 | FQ end 2026-06
How IOVA's past catalysts played out
Lifileucel plus Pembrolizumab
Metastatic Melanoma
Pembrolizumab
Metastatic Melanoma
IOV-3001
Unresectable Melanoma
IOV-2001
Chronic Lymphocytic Leukemia
LN-145-S1
Squamous Cell Carcinoma of the Head and Neck
Lifileucel
Endometrial Cancer
LN-145
Metastatic Non Small Cell Lung Cancer
IOV-4001
Unresectable Melanoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lifileucel plus Pembrolizumab | Phase 3 | Metastatic Melanoma | - | - |
Pembrolizumab | Phase 2 | Metastatic Melanoma | - | - |
IOV-3001 | Phase 2 | Unresectable Melanoma | - | - |
IOV-2001 | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
LN-145-S1 | Phase 2 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Lifileucel | Phase 2 | Endometrial Cancer | - | - |
LN-145 | Phase 2 | Metastatic Non Small Cell Lung Cancer | - | - |
IOV-4001 | Phase 2 | Unresectable Melanoma | - | - |
Metastatic Melanoma
2 drugs in this indication
Unresectable Melanoma
2 drugs in this indication
Chronic Lymphocytic Leukemia
1 drug in this indication
Squamous Cell Carcinoma of the Head and Neck
1 drug in this indication
Endometrial Cancer
1 drug in this indication
Metastatic Non Small Cell Lung Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Iovance Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Iovance Biotherapeutics, Inc.'s (IOVA) pipeline across Phase 3, Phase 2. Its lead program is Lifileucel plus Pembrolizumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Iovance Biotherapeutics, Inc.'s next FDA catalyst?→
Iovance Biotherapeutics, Inc.'s (IOVA) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IOVA biotech catalysts?→
Add IOVA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Iovance Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.